Core Wealth Advisors LLC Invests $505,000 in Merck & Co., Inc. $MRK

Core Wealth Advisors LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,798 shares of the company’s stock, valued at approximately $505,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Chesapeake Wealth Management boosted its position in Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after purchasing an additional 87 shares in the last quarter. Syverson Strege & Co boosted its position in Merck & Co., Inc. by 2.2% during the fourth quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after purchasing an additional 90 shares in the last quarter. Westside Investment Management Inc. boosted its position in Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after purchasing an additional 93 shares in the last quarter. Valued Wealth Advisors LLC boosted its position in Merck & Co., Inc. by 26.9% during the fourth quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after purchasing an additional 94 shares in the last quarter. Finally, Intrua Financial LLC boosted its position in Merck & Co., Inc. by 1.1% during the fourth quarter. Intrua Financial LLC now owns 8,604 shares of the company’s stock valued at $906,000 after purchasing an additional 96 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MRK shares. UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Barclays started coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They set an “overweight” rating and a $140.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Cantor Fitzgerald raised their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $118.49 on Friday. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The company has a market cap of $292.66 billion, a PE ratio of 33.38, a P/E/G ratio of 2.67 and a beta of 0.18. The business has a 50-day simple moving average of $116.39 and a two-hundred day simple moving average of $111.46. Merck & Co., Inc. has a fifty-two week low of $75.40 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA granted Breakthrough Therapy designation to calderasib (MK-1084) with Keytruda in a lung cancer indication, a sign the program may move faster and expand Merck’s oncology growth prospects. Article Title
• Positive Sentiment: Analyst coverage and recent articles highlighted Merck’s newer drugs, pipeline assets, and M&A options as potential offsets to looming Keytruda patent expiration, reinforcing the bull case for long-term growth. Article Title
• Positive Sentiment: Merck has also been drawing investor attention as a trending stock and has outperformed the S&P 500 over the past year, suggesting market confidence remains relatively strong. Article Title
• Neutral Sentiment: Merck will participate in the Jefferies Global Healthcare Conference, which could provide an update on strategy but is not itself a major business catalyst. Article Title
• Neutral Sentiment: Shareholders backed board nominees, pay, and auditor ratification at the annual meeting, which reduces governance uncertainty but is unlikely to move the stock much. Article Title
• Negative Sentiment: The main longer-term concern remains Keytruda’s eventual loss of exclusivity, which could pressure Merck’s biggest revenue driver if replacement products do not scale quickly enough. Article Title

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.